Status:
RECRUITING
Neuroprognostication Bias: A Collaboration to Reduce the Impact of Self-fulfilling Prophecy in Cardiac ARrEst
Lead Sponsor:
Boston Medical Center
Collaborating Sponsors:
University of Florida
Hospital Israelita Albert Einstein
Conditions:
Cardiac Arrest
Eligibility:
All Genders
18-89 years
Brief Summary
Cardiovascular disease remains the leading cause of death in the United States. Mortality rates of cardiac arrest range from 60-85%, and approximately 80% of survivors are initially comatose. Of those...
Detailed Description
SPARE is a multi-center, international, prospective registry designed to evaluate the use of a multi-modality approach to neuroprognostication after cardiac arrest. Subjects will be evaluated with sta...
Eligibility Criteria
Inclusion
- Initially unconscious following cardiac arrest from any non-perfusing rhythm (i.e., ventricular tachycardia, ventricular fibrillation, pulseless electrical activity, asystole)
- Sustained return of spontaneous circulation (ROSC) as defined by maintained spontaneous circulation for at least 20 minutes after cardiopulmonary resuscitation.
Exclusion
- \- Isolated respiratory arrest without concomitant or ensuing cardiac arrest
Key Trial Info
Start Date :
August 2 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2027
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT03261089
Start Date
August 2 2017
End Date
August 1 2027
Last Update
December 24 2025
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Francisco
San Francisco, California, United States, 94143
2
Yale University
New Haven, Connecticut, United States, 06510
3
University of Florida
Gainesville, Florida, United States, 32611
4
Boston Medical Center
Boston, Massachusetts, United States, 02118